CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in MS
COVID-19 vaccine response in people with multiple sclerosis
Immunogenicity of biologics used in the treatment of moderate to severe psoriasis
Immunogenicity of biologics used in the treatment of inflammatory bowel disease: A review
Anti-drug antibodies to antibody-based therapeutics in multiple sclerosis
Mapping the T cell response to COVID-19
Detecting and predicting neutralization of Alemtuzumab responses in Multiple Sclerosis.
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic